Skip to main content
Fig. 5 | Journal for ImmunoTherapy of Cancer

Fig. 5

From: Targeting the tumor stroma with an oncolytic adenovirus secreting a fibroblast activation protein-targeted bispecific T-cell engager

Fig. 5

Enhanced antitumor efficacy of ICO15K-FBiTE in the presence of T cells. a-e NSG mice bearing subcutaneous A549 (lung carcinoma) or HPAC (pancreatic adenocarcinoma) tumors were intratumorally treated with PBS, ICO15K, or ICO15K-FBiTE (1 × 109 vp/tumor). a. Antitumor activity in absence of T cells. Mean percentage of tumor growth value ± SEM with ≥12 tumors per group is plotted. b-e Antitumor efficacy in the presence of T cells. Four days after virus treatment, animals were treated once (HPAC) or twice (A549) with 1 × 107 preactivated T cells. The mean tumor growth ± SEM of ≥12 tumors per group is shown. d, e Kaplan-Meier survival curves of the experiments described in b and c. *, significant (P < 0.05) by one-way ANOVA test with post hoc analysis compared to ICO15K group. #, significant (P < 0.05) by one-way ANOVA test with post hoc analysis compared to PBS group

Back to article page